KLF6 IVS1 -27G>A Variant and the Risk of Prostate Cancer in Finland

• Published in: European urology Vol. 52; no. 4; pp. 1076 - 1081
• Main Authors: Seppälä, Eija H, Autio, Ville, Duggal, Priya, Ikonen, Tarja, Stenman, Ulf-Håkan, Auvinen, Anssi, Bailey-Wilson, Joan E, Tammela, Teuvo L.J, Schleutker, Johanna
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier 01.10.2007
• Subjects: Adenine; Biological and medical sciences; Finland - epidemiology; Genetic Variation; Genotype; Germ-Line Mutation; Guanine; Gynecology. Andrology. Obstetrics; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors - blood; Kruppel-Like Transcription Factors - genetics; Male; Male genital diseases; Medical sciences; Nephrology. Urinary tract diseases; Polymorphism, Single Nucleotide; Prostatic Hyperplasia - epidemiology; Prostatic Hyperplasia - genetics; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - genetics; Proto-Oncogene Proteins - blood; Proto-Oncogene Proteins - genetics; Risk Factors; Tumor Suppressor Proteins - genetics; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Urology; Europe; Finland; Association study; Cancer susceptibility; KLF6; Benign prostate hyperplasia; Prostate cancer; Nephrology; Urinary system disease; Genetic variability; Prostate disease; Genotype; Malignant tumor; Epidemiology; Urology; Variant; Association; Kruppel like factor 6; Risk factor; Benign prostatic hyperplasia; Benign neoplasm; Male genital diseases
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2006.11.019

Abstract Objectives A recent report demonstrated that KLF6 IVS1 -27G>A substitution increases the transcription of alternatively spliced isoforms; this action was suggested to be associated with prostate cancer (pCA). To evaluate these findings among the Finnish population, a total of 3348 samples were analysed. Methods The variant was genotyped in 164 patients with familial pCA, 852 patients with unselected pCA, 459 patients with benign prostate hyperplasia (BPH), 923 male population controls, and 950 men from a Finnish prostate-specific antigen (PSA) screening trial with PSA levels less than 1.0 ng/ml. Odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated by using logistic regression to estimate pCA risk. Results Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56–1.28; p = 0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76–1.19; p = 0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86–1.46; p = 0.39). pCA and BPH cases were also compared with PSA-screened controls. None of these analyses revealed any significant associations. Conclusions Our results do not support the suggested association of KLF6 IVS1 -27G>A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.